We examined the inhibitory activity against bacterial peptidoglycan biosynthesis, mammalian glycoprotein biosynthesis and growth of BALB/3T3 cells of four different types of liposidomycins which have the structure with or without sulfate and/or 3-methylglutaric acid moieties. Liposidomycins inhibited peptidoglycan biosynthesis about tunicamycin.
We examined the inhibitory activity against bacterial peptidoglycan biosynthesis, mammalian glycoprotein biosynthesis and growth of BALB/3T3 cells of four different types of liposidomycins which have the structure with or without sulfate and/or 3-methylglutaric acid moieties. Liposidomycins inhibited peptidoglycan biosynthesis about tunicamycin.
When the cytotoxic effect of liposidomycins and tunicamycin on the growth of mammalian cells were compared, liposidomycins did not show toxicity against B and mureidomycin A were shown to act as slow-binding inhibitors, whereas tunicamycin has a reversible inhibition mechanism9 After incubation, the reaction mixture was added into 1ml of cold 5 % TCA and filtered through a Whatmann GF/C glass filter. The filter was washed with 5% TCA two times and the remaining radioactivity was counted by an Aloka liquid scintillation counter with a toluene-based scintillation fluid.
Assay of DoI-PP-GIcNAc Biosynthesis
For the assay of dolichyl-pyrophosphoryl-N-acetylglucosamine (Dol-PP-GlcNAc) formation, microsomes were prepared from rat livers. A reaction mixture containing microsomes (4mg protein/ml), 10mM Tris-malate buffer THE JOURNAL OF ANTIBIOTICS 1101 
Assay of Cytotoxicity
Assay of Antimicrobial Activity Antimicrobial activity was measured using the conventional paper disc method.
Results

Inhibition of Peptidoglycan Biosynthesis
Peptidoglycan inhibitory activity of typical four types of liposidomycins (A-(I), A-(II), A-(III) and A-(IV)) and tunicamycin were shown in Table 1 
Inhibition of DoI-PP-GlcNAc Biosynthesis
DoI-PP-GlcNAc biosynthesis inhibitory activity of typical four types of liposidomycins (A-(I), A-(II), A-(III)
and A-(IV)) and tunicamycin were shown in Fig. 3 Table 3 . Antimicrobial activity against various microorganisms of liposidomycin C-(III) and tunicamycin.
Discussion
Liposidomycins act as potent and selective inhibitors of bacterial translocase I, which catalyzes the first step in the membrane cycle of bacterial cell wall peptidoglycan biosynthesis. Although it was reported that tunicamycin7), amphomycin15) and mureidomycin8) also inhibited translocase I, this target remains unexploited for therapeutic antibiotics (Fig. 1) . Though liposidomycins are fascinating antibiotics in structure and in specific translocase I inhibitory activity, the antimicrobial activity was not strong enough in the original type (I) compounds5). We isolated new types of liposidomycins with more potent antimicrobial activity11). The nonsulfate type (type (III) and (IV)) had potent antimicrobial activity12). We examined the inhibition activity of all four types of liposidomycins against peptidoglycan biosynthesis, glycoprotein biosynthesis and cell growth. Though type (III) and (IV) had almost the same or less potency as type (I) and (II) against peptidoglycan biosynthesis in vitro, they had improved antimicrobial activity against bacteria, especially Mycobacterium phlei IFO3158. This indicated that type (III) and (IV) might be able to penetrate through the cell membrane and inhibit the translocase I located in the inner cytoplasmic membrane.
Tunicamycin is also a nucleoside antibiotic which has uracil, tunicamine, GlcNAc and lipid side chains (Fig.  2.)16) . Though it inhibited the same site of bacterial peptidoglycan biosynthesis as liposidomycin, it inhibited the mammalian glycoprotein biosynthesis more strongly similarity to tunicamycin (Fig. 2.) , it inhibited peptidoglycan biosynthesis more potently than glycoprotein biosynthesis. Unique structural features, such as the amino sugar of liposidomycin, 5-amino-5-deoxyribose OF ANTIBIOTICS DEC. 1998 and/or perhydro-1, 4-diazepine moieties might be involved with this specific biological activitiy against peptidoglycan biosynthesis. These results indicated that liposidomycin is a highly potent and selective inhibitor of bacterial peptidoglycan biosynthesis and could lead to the design of useful clinical antibiotic agents.
